Evogene’s Q2 Revenues Rise, Loss Trimmed

Aug 31, 2007

Agricultural biotech firm Evogene announced this week that its second quarter revenues rose to $129,000 from $10,500 in the second quarter last year.

The Israeli firm posted a net loss of $738,000, or $.05 per share, for the three months ended June 30, compared with a net loss of $836,000, or $.06 per share, for the comparable period a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Cloud Ready

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

The Science and Policy Connection

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

The New Yeast

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

This Week in Cell

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.

Main menu